Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 14, Issue 3 (May 2012) 14, 405–408; 10.1038/aja.2011.149

Cyr61 is a potential prognostic marker for prostate cancer

Naoki Terada1, Prakash Kulkarni1,2 and Robert H Getzenberg1,2,3

1 Department of Urology, the James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2 Department of Urology Oncology, The Johns Hopkins University School of Medicine, Baltimore, Baltimore, MD 21287, USA
3 Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

Correspondence: Dr RH Getzenberg, (rgetzen1@jhmi.edu)

Received 16 September 2011; Revised 29 November 2011; Accepted 29 November 2011; Advance online publication 20 February 2012

Abstract

Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer (PCa), Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.

Keywords: Cyr61; lethal prostate cancer; non-lethal prostate cancer; overdiagnosis; overtreatment; prostate cancer

PDF | 中文摘要 |

 
Browse:  360
Copyright 1999-2014    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved